Profilo
Pavel Hamet was the founder of Prognomix, Inc. (2005) with the title of President, Co-Chief Executive Officer & Director.
Current jobs include Director at Bellus Health (Innodia), Inc., Director at Canadian Institutes of Health Research, Director at Medpharmgene, Inc., Director at Société Francophone Du Diabete since 2010, and Professor at the University of Montréal.
Former jobs include Chairman at Canada Foundation for Innovation, Director at AGC Biologics SpA, Director at BioCapital Investment Advisors, Inc. from 2003 to 2005, Director at Société de développement Angus, and President at Canadian Hypertension Society.
Education includes a doctorate from McGill University (1972) and a doctorate from the University of Charles (1967).
Posizioni attive di Pavel Hamet
| Società | Posizione | Inizio |
|---|---|---|
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Direttore/Membro del Consiglio | - |
Canadian Institutes of Health Research
Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities | Direttore/Membro del Consiglio | 02/06/2010 |
University of Montréal
University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Société Francophone Du Diabete | Direttore/Membro del Consiglio | 01/01/2010 |
Medpharmgene, Inc.
Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Pavel Hamet
| Società | Posizione | Fine |
|---|---|---|
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Fondatore | 13/01/2015 |
BioCapital Investment Advisors, Inc.
BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Direttore/Membro del Consiglio | 31/12/2005 |
Société de développement Angus
Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects | Direttore/Membro del Consiglio | - |
Canadian Hypertension Society | Presidente | - |
| ░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Pavel Hamet
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
AGC Biologics SpA
AGC Biologics SpA Pharmaceuticals: MajorHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cells & gene therapies and messenger RNA | Health Technology |
BioCapital Investment Advisors, Inc.
BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody. | Finance |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Montréal
University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
University of Charles
University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prognomix, Inc.
Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications | Health Technology |
Canada Foundation For Innovation
Canada Foundation For Innovation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Canadian Institutes of Health Research
Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities | Commercial Services |
Canadian Hypertension Society | |
Medpharmgene, Inc.
Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services | Commercial Services |
Société de développement Angus
Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects | Finance |
Société Francophone Du Diabete |
















